RT Journal Article
SR Electronic
T1 Emergence and Persistent Dominance of Omicron BA.2.3.7 Variant in Community Outbreaks in Taiwan
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.09.27.22280238
DO 10.1101/2022.09.27.22280238
A1 Shao, Pei-Lan
A1 Tu, Hsiao-Chen
A1 Gong, Yu-Nong
A1 Shu, Hung-Yu
A1 Kirby, Ralph
A1 Hsu, Li-Yun
A1 Yeo, Hui-Yee
A1 Kuo, Han-Yueh
A1 Huang, Yi-Chia
A1 Lin, Yung-Feng
A1 Weng, Hui-Ying
A1 Wu, Yueh-Lin
A1 Chen, Chien-Chih
A1 Chen, Tzen-Wen
A1 Lee, Kuo-Ming
A1 Huang, Chung-Guei
A1 Shih, Shin-Ru
A1 Chen, Wei J
A1 Wu, Chen-Chi
A1 Yu, Chong-Jen
A1 Tsai, Shih-Feng
YR 2023
UL http://medrxiv.org/content/early/2023/01/10/2022.09.27.22280238.abstract
AB Since April 2022, waves of Omicron cases have surfaced in Taiwan and spread throughout the island. Using high-throughput sequencing of the SARS-CoV-2 genome, we have analyzed 2405 PCR-positive swab samples from 2339 individuals and identified the Omicron BA.2.3.7 variant as a major lineage within the recent community outbreak in Taiwan.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by Ministry of Health and Welfare of Taiwan (MOHW110-TDU-C-222-000010) to S.F.T., by the Research Center for Emerging Viral Infections from The Featured Areas Research Center Program within the framework of the Higher Education Sprout Project by the Ministry of Education (MOE) of Taiwan, the National Science and Technology Council (NSTC), Taiwan (NSTC 111-2321-B-182-001, 111-2634-F-182-001, and 111-2221-E-182-053-MY3), and the National Institute Of Allergy And Infectious Diseases of the National Institutes of Health under Award Number 5U01AI151698-02 to Y.N.G. and S.R.SAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee/IRB of National Taiwan University Hospital Hsin-Chu Branch gave 110-110-E ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors